Steindl Ariane, Brastianos Priscilla K, Preusser Matthias, Berghoff Anna S
Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Neurooncol Adv. 2021 Nov 27;3(Suppl 5):v35-v42. doi: 10.1093/noajnl/vdab105. eCollection 2021 Nov.
Brain metastases (BM) present a common cause of mortality and morbidity in several metastatic cancer entities. New therapeutic developments during the last decades, including targeted and immune-related therapies, have shown considerable extra- and intracranial response rates in specific subgroups of BM patients. However, differences in the molecular alteration in the BM tumor tissue compared to extracranial tumors leads to heterogeneous therapeutic responses. Therefore, an accurate molecular analyzation of BM tissue, if possible, has become an essential part in therapeutic decision making in BM patients. The concordance of predictive molecular biomarkers between multiple sites including extracranial and intracranial tumor tissue have been analyzed for some but not all biomarkers routinely applied in modern precision medicine approaches. In the present review, we summarize the current evidence of predictive biomarkers for personalized therapy approaches in the treatment of parenchymal BM.
脑转移瘤（BM）是多种转移性癌症实体中导致死亡和发病的常见原因。在过去几十年中，包括靶向治疗和免疫相关治疗在内的新治疗进展，在特定亚组的BM患者中显示出相当可观的颅外和颅内缓解率。然而，与颅外肿瘤相比，BM肿瘤组织分子改变的差异导致治疗反应的异质性。因此，如果可能的话，对BM组织进行准确的分子分析已成为BM患者治疗决策的重要组成部分。对于现代精准医学方法中常规应用的一些但并非所有生物标志物，已经分析了包括颅外和颅内肿瘤组织在内的多个部位之间预测性分子生物标志物的一致性。在本综述中，我们总结了目前关于实质性BM治疗中个性化治疗方法预测生物标志物的证据。
